Amerikanische Gesellschaft für Hirudotherapie

Secondary Trigeminal Neuralgia (Investigational Adjunct)

Highly investigational adjunct for secondary trigeminal neuralgia after MRI evaluation; carbamazepine and oxcarbazepine remain first-line; microvascular decompression for refractory cases.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for trigeminal neuralgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for secondary trigeminal neuralgia is investigational.
Welche Evidenz existiert?
Tier C (investigational). Only case reports; there are no randomized controlled trials. Evidence-based therapy for trigeminal neuralgia: carbamazepine or oxcarbazepine as first-line (AAN-endorsed), with lamotrigine, baclofen, or gabapentin as alternatives. Microvascular decompression surgery in selected fit patients (long-term pain relief >70 percent). Gamma knife radiosurgery and percutaneous procedures (glycerol injection, balloon compression, radiofrequency thermocoagulation) for medically refractory disease. Secondary causes (multiple sclerosis, tumor) require treatment of the underlying disease.
Hauptrisiken
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Trigger of acute trigeminal pain attack at bite locations on the face
  • Local skin infection or, rarely, Aeromonas infection on the face
  • Allergic reaction to leech saliva (uncommon)
  • Post-inflammatory hyperpigmentation or scarring on the face
  • Risk if leech placed too close to the eye or ophthalmic branch
  • Delay of carbamazepine, microvascular decompression, or workup for secondary causes
  • Risk of missed multiple sclerosis or tumor as cause of secondary trigeminal neuralgia
Wer dies nicht in Betracht ziehen sollte
  • Patients who have not been worked up for multiple sclerosis or tumor (MRI required)
  • Patients with active herpes zoster of the trigeminal nerve
  • Patients with eye involvement or first-division (V1) trigeminal pain (specialty care)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried carbamazepine or oxcarbazepine
  • Patients with darker Fitzpatrick skin types at high PIH risk on the face
Was Sie Ihren Kliniker fragen sollten
  • Have I had an MRI brain to rule out multiple sclerosis or tumor?
  • Have I tried carbamazepine or oxcarbazepine at therapeutic doses?
  • Am I a candidate for microvascular decompression or gamma knife radiosurgery?
  • What evidence specifically supports leech therapy for trigeminal neuralgia?
  • What is the risk of triggering a pain attack with facial leech bites?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
Wann dringende medizinische Versorgung suchen
  • New double vision, eye pain, or vision loss (cranial nerve or eye involvement)
  • Sudden severe facial weakness or numbness (possible stroke or tumor progression)
  • New limb weakness, balance problems, or vision changes (possible MS exacerbation)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for trigeminal neuralgia.
  • Case reports do NOT establish efficacy versus carbamazepine, microvascular decompression, or gamma knife radiosurgery.
  • It does NOT replace MRI workup for secondary causes (MS, tumor) in secondary trigeminal neuralgia.
  • It does NOT substitute for evidence-based pharmacologic or surgical therapy.
  • It does NOT mean facial leech application is safe — pigment changes and scarring are facial-cosmetic concerns.

Clinical Profile

Category
neurological
ICD-10
G50.0
Safety tier
high

Evidence Summary

Trigeminal neuralgia (TN) involves paroxysmal lancinating facial pain in trigeminal distribution. Classical TN is often associated with neurovascular compression at the root entry zone; secondary TN may relate to multiple sclerosis or tumor. Per AAN and EFNS guidance, first-line therapy is carbamazepine or oxcarbazepine; surgical options for refractory cases include microvascular decompression, percutaneous procedures, and stereotactic radiosurgery. No controlled clinical trial of hirudotherapy for trigeminal neuralgia has been published; any use is investigational and mechanistic only. MRI evaluation must be completed before any adjunctive consideration.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Krashenyuk AI (2010)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • MRI not completed (intracranial mass or MS demyelination must be excluded)
  • Facial placement directly on trigeminal distribution
  • Placement over temporal artery (risk of arterial bleeding)
  • Discontinuation of first-line pharmacotherapy
  • Active dental or sinus pathology mimicking TN

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Secondary Trigeminal Neuralgia (Investigational Adjunct) — Hirudotherapy Evidence | ASH